Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial

Lancet

Volumn 358, Issue 9297, 2001, Pages 1927-1934

  Bojang, Kalifa A ^a   Milligan, Paul J M ^a   Pinder, Margaret ^a   Vigneron, Laurence ^e   Alloueche, Ali ^b   Kester, Kent E ^d   Ballou, W Ripley ^d   Conway, David J ^b   Reece, William H H ^c   Gothard, Philip ^c   Yamuah, Lawrence ^a   Delchambre, Martine ^e   Voss, Gerald ^e   Greenwood, Brian M ^b   Hill, Adrian ^c   McAdam, Keith P W J ^a   Tornieporth, Nadia ^e   Cohen, Joe D ^e   Doherty, Tom ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; MEMBRANE PROTEIN; PYRIMETHAMINE; RABIES VACCINE; RTS S ASO2; SULFADOXINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SMEAR; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FOLLOW UP; GAMBIA; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOROZOITE;

EID: 0035830278     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06957-4     Document Type: Article

References (32)

1. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia
2. A population based clinical trial with SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela
3. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo controlled field trial in an area of Ecuador
4. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in Southern Tanzania
5. Efficacy trial of malaria vaccine SPf66 in Gambian infants
6. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand
7. Evaluation of SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania
8. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
9. Long-term efficacy and immune response following immunization with RTS,S malaria vaccine
10. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia
11. A review of the epidemiology and control of malaria in The Gambia, West Africa
12. Malaria prevalence is inversely related to vector density in The Gambia, West Africa
13. Comparison of two simple methods for determining malaria parasite density
14. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine
15. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine
16. High throughput sequence typing of T-cell epitope polymorphisms in Plasmodium falciparum circumsporozoite protein
17. Comparison of two smoothing methods for exploring waning vaccine effects
18. The impact of heterogeneity on the comparison of survival times
19. Heterogeneity in survival analysis
20. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria
21. Circumventing genetic restriction of protection against malaia with multigene DNA immunization: CD8+cell-, interferon gamma-, nitric oxide-dependent immunity
22. IgM antibody responses to the circumsporozoite protein in naturally acquired falciparum malaria
23. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
24. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
25. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum
26. Characterization of antibodies to sporozoite of Plasmodium falciparum malaria and correlation with protection
27. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites
28. Research towards vaccine against malaria
29. Insecticide treated bednets and curtains for malaria control